{"title":"【多发性骨髓瘤诊断和治疗的最新进展】。","authors":"Artur Jurczyszyn, Magdalena Olszewska-Szopa","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Recently a great progress in the\ndiagnosis and treatment of multiple\nmyeloma has been made. Substantial\nrevisions in diagnostic criteria were introduced.\nAs a result a neoplasm called\nvery high risk asymptomatic myeloma\nis currently regarded a disease that\nneeds to be treated. The comprehension\nof progression mechanism and\nclonal evolution not only helped to\nunderstand the disease course but\nmight contribute to expand treatment\noptions and individualize the therapy.\nModern triple therapy containing IMiDs\nand proteasome inhibitors resulted\nin the higher response rate than ever\nbefore which led to triple therapy incorporation\nas a frontline treatment.\nU.S. Food and Drug Administration\n(FDA) registered for new drugs in\n2015 (two monoclonal antibodies and\ntwo oral drugs) in relapsed/refractory\nmyeloma. Together with currently existing\ndrugs it considerably expended\nthe therapeutically spectrum. Even\ndrugs that are not effective when used\nas a monotherapy like panobinostat\nand elotuzumab play important role\nin complex therapy, particularly in\nrefractory patients. The most recent\ntrials dedicated to the role of the novel\ndrugs in the induction phase suggest\nthat high–dose therapy followed by\nautologous stem cell transplantation\nimprove progression free survival\nand quality of life. Myeloma treatment\nschedules incorporate more and more\ninnovative immunotherapy methods:\nadoptive T-cell therapies, vaccines\nand monoclonal antibodies. Although\nmultiple myeloma is still regarded\nincurable neoplasm, due to better\ndisease understanding and access to\nnovel drugs, we are getting closer than\never before to evolve therapy that will\nprovide long-lasting effects or at least\nconverting it into the chronic slowly\ndeveloping disease.</p>","PeriodicalId":21148,"journal":{"name":"Przeglad lekarski","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[The most recent developments in diagnosis and treatment of multiple myeloma].\",\"authors\":\"Artur Jurczyszyn, Magdalena Olszewska-Szopa\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Recently a great progress in the\\ndiagnosis and treatment of multiple\\nmyeloma has been made. Substantial\\nrevisions in diagnostic criteria were introduced.\\nAs a result a neoplasm called\\nvery high risk asymptomatic myeloma\\nis currently regarded a disease that\\nneeds to be treated. The comprehension\\nof progression mechanism and\\nclonal evolution not only helped to\\nunderstand the disease course but\\nmight contribute to expand treatment\\noptions and individualize the therapy.\\nModern triple therapy containing IMiDs\\nand proteasome inhibitors resulted\\nin the higher response rate than ever\\nbefore which led to triple therapy incorporation\\nas a frontline treatment.\\nU.S. Food and Drug Administration\\n(FDA) registered for new drugs in\\n2015 (two monoclonal antibodies and\\ntwo oral drugs) in relapsed/refractory\\nmyeloma. Together with currently existing\\ndrugs it considerably expended\\nthe therapeutically spectrum. Even\\ndrugs that are not effective when used\\nas a monotherapy like panobinostat\\nand elotuzumab play important role\\nin complex therapy, particularly in\\nrefractory patients. The most recent\\ntrials dedicated to the role of the novel\\ndrugs in the induction phase suggest\\nthat high–dose therapy followed by\\nautologous stem cell transplantation\\nimprove progression free survival\\nand quality of life. Myeloma treatment\\nschedules incorporate more and more\\ninnovative immunotherapy methods:\\nadoptive T-cell therapies, vaccines\\nand monoclonal antibodies. Although\\nmultiple myeloma is still regarded\\nincurable neoplasm, due to better\\ndisease understanding and access to\\nnovel drugs, we are getting closer than\\never before to evolve therapy that will\\nprovide long-lasting effects or at least\\nconverting it into the chronic slowly\\ndeveloping disease.</p>\",\"PeriodicalId\":21148,\"journal\":{\"name\":\"Przeglad lekarski\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2017-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Przeglad lekarski\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Przeglad lekarski","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
[The most recent developments in diagnosis and treatment of multiple myeloma].
Recently a great progress in the
diagnosis and treatment of multiple
myeloma has been made. Substantial
revisions in diagnostic criteria were introduced.
As a result a neoplasm called
very high risk asymptomatic myeloma
is currently regarded a disease that
needs to be treated. The comprehension
of progression mechanism and
clonal evolution not only helped to
understand the disease course but
might contribute to expand treatment
options and individualize the therapy.
Modern triple therapy containing IMiDs
and proteasome inhibitors resulted
in the higher response rate than ever
before which led to triple therapy incorporation
as a frontline treatment.
U.S. Food and Drug Administration
(FDA) registered for new drugs in
2015 (two monoclonal antibodies and
two oral drugs) in relapsed/refractory
myeloma. Together with currently existing
drugs it considerably expended
the therapeutically spectrum. Even
drugs that are not effective when used
as a monotherapy like panobinostat
and elotuzumab play important role
in complex therapy, particularly in
refractory patients. The most recent
trials dedicated to the role of the novel
drugs in the induction phase suggest
that high–dose therapy followed by
autologous stem cell transplantation
improve progression free survival
and quality of life. Myeloma treatment
schedules incorporate more and more
innovative immunotherapy methods:
adoptive T-cell therapies, vaccines
and monoclonal antibodies. Although
multiple myeloma is still regarded
incurable neoplasm, due to better
disease understanding and access to
novel drugs, we are getting closer than
ever before to evolve therapy that will
provide long-lasting effects or at least
converting it into the chronic slowly
developing disease.